CAH

Business profile & competitive position

Cardinal Health, Inc. operates in the Healthcare sector, specifically the Medical - Distribution industry. Its core business is supplying pharmaceuticals, medical products, and related services that are designed to make healthcare supply chains more efficient. The company connects patients, providers, payers, pharmacists, and manufacturers, and reports through two main segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution, plus a smaller Other category.

For fiscal 2026, Cardinal Health generated $254.2 billion in revenue, up 14% year over year. The Pharmaceutical and Specialty Solutions segment drove most of that growth, with revenue rising 15% to $234.8 billion on branded and specialty pharmaceutical growth. Non-GAAP operating earnings increased 30% to $3.6 billion, while GAAP operating earnings rose 15% to $2.6 billion.

The financial profile of a distributor is reflected in the margin figures. The net margin is 0.7%, which is consistent with a high-volume, low-touch distribution model where profitability comes from turnover rather than markup. Meanwhile, ROE is reported at -59.7%. That negative reading does not match the positive operating earnings trend, so it is better understood as a balance-sheet or accounting artifact rather than a signal of operating collapse. Combined with a beta of 0.50, the stock has traded with noticeably lower volatility than the broader market. The competitive moat here is scale and logistics reach across a $254.2 billion revenue base, not outsized pricing power.

Financial posture

Cardinal Health’s current market capitalization is $55.6 billion. The stock is trading at $237.57, with a 50-day EMA of $230.58 and an RSI of 59.5, which sits just below commonly watched overbought thresholds. The P/E ratio is 32.7, the net margin is 0.7%, ROE is -59.7%, and beta is 0.50.

A P/E of 32.7 is elevated when set against a 0.7% net margin. That valuation multiple appears to be pricing in continued earnings growth and the defensive nature of healthcare distribution rather than margin expansion. The negative ROE figure again stands out: with GAAP operating earnings rising 15% to $2.6 billion, the negative return on equity likely reflects capital-structure items, shareholder distributions, or balance-sheet adjustments rather than deteriorating operations. Beta of 0.50 means the stock has historically moved about half as much as the overall market, consistent with a healthcare-services business that is less tied to the economic cycle.

Strategic priorities & outlook

Cardinal Health’s most recent 10-K filing outlines several near-term operational priorities. The company plans to expand and integrate the Specialty Alliance multi-specialty MSO platform and other acquired physician-practice support platforms to capture expected value. On November 3, 2025, Cardinal Health completed the acquisition of Solaris Health, a urology MSO, for roughly $1.9 billion, and afterward owned approximately 76% of The Specialty Alliance.

In the Global Medical Products and Distribution segment, management aims to reduce tariff impacts through cost optimization and by passing through higher prices on affected products. For the pharmaceutical business, the focus is on managing the generics program, including new product launches, customer volumes, pricing, Red Oak Sourcing, and contract manufacturing and sourcing costs. The company is also targeting approximately $700 million in fiscal 2027 capital expenditures for manufacturing, distribution infrastructure, and technology investments.

Macro & geopolitical exposure

As a medical distributor, Cardinal Health is exposed to several macro and policy forces. The pharmaceutical distribution business is sensitive to drug pricing regulation, generic deflation, 340B drug-pricing policies, and enforcement actions by agencies such as the DEA. It also carries the long-term overhang of opioid-related litigation and settlement obligations that have affected major drug distributors.

The Global Medical Products and Distribution segment adds exposure to tariffs, especially on medical supplies and devices sourced internationally, as well as to supply-chain reshoring costs and currency swings on non-U.S. operations. Reimbursement pressure from Medicare and Medicaid can also affect demand and pricing for distributed products. Logistics, labor, and transportation costs round out the operational sensitivity list for a business that moves physical inventory at massive scale.

Recent developments

Recent coverage of Cardinal Health has been mixed in tone but light on material news. On October 6, 2026, Zacks published “Reasons to Retain Cardinal Health Stock in Your Portfolio for Now.” The same outlet noted on October 5, 2026, in “Cardinal Health (CAH) Outperforms Broader Market: What You Need to Know,” that the stock had outpaced the broader market. On the same day, institutional-flow headlines showed divergent activity: defenseworld.net reported that Park National Corp OH decreased its CAH position, while MassMutual Private Wealth & Trust FSB bought 106,709 shares. These cross-currents illustrate institutional repositioning rather than a clear directional consensus.

Earnings behavior & post-earnings drift

Cardinal Health has delivered an impressive earnings track record over the last eight quarters, beating expectations in all eight, for a 100% beat rate. The average earnings surprise during that span was 12.5%. Yet the average 5-day price move following those reports was -1.8%, classified as a “down” drift. That divergence is the central pattern to understand: a beat has not reliably translated into sustained upward price pressure.

The last four reports make the point in detail. On August 11, 2026, CAH reported EPS of $2.91 against an estimate of $2.42, a 20.2% positive surprise, but the stock fell 2.54% the next day and 2.2% over the following five days. On April 30, 2026, EPS of $3.17 beat the $2.79 estimate by 13.6%; the stock rose 1.22% the next session but then dropped 3.94% over the next five days. On February 5, 2026, EPS of $2.63 beat the $2.34 estimate by 12.4%; the next-day move was -0.38%, and the five-day drift was -5.33%. Only the October 30, 2025 report, where EPS of $2.55 beat the $2.18 estimate by 17%, produced a positive five-day drift of 4.29% after a 0.49% next-day gain.

So over three of the last four quarters, CAH beat estimates and still slipped over the following week. The next scheduled report is November 5, 2026, before the market opens, with a consensus EPS estimate of $2.95. Traders should be aware that Cardinal Health’s history suggests beats are frequently priced in, or even sold, shortly after the release.

For investors seeking a deeper perspective on CAH, the full institutional verdict aggregates sell-side ratings, target ranges, and consensus positioning. That resource can help contextualize the divergence between Cardinal Health’s 100% earnings beat rate and its negative average post-earnings drift.